Abstract
Molecularly targeted medicine poses substantial challenges for incorporation into the existing U.S. health care system. It is argued here that performance-based risk-sharing arrangements may be a promising approach to address the competing needs of patients, clinicians, and payers.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
